<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intralesional corticosteroid injection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intralesional corticosteroid injection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intralesional corticosteroid injection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara M Mathes, MD, FACP, FAAD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick C Alguire, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily Gurnee, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert P Dellavalle, MD, PhD, MSPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intralesional injection (ie, direct delivery of medication percutaneously into skin lesions) has been an important part of dermatologic therapy since it was first introduced in 1961 [
         <a href="#rid1">
          1,2
         </a>
         ]. Intralesional injections are effective for a wide range of indications, are easily performed, and are relatively safe.
        </p>
        <p>
         The drugs primarily used for intralesional injections are corticosteroids, but
         <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">
          bleomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and interferons have also been dispensed in this manner [
         <a href="#rid3">
          3-8
         </a>
         ]. This topic will review the indications, techniques, and adverse effects of intralesional injection of corticosteroids. The use and adverse effects of topical and systemic corticosteroids are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/124.html" rel="external">
          "Pharmacologic use of glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H358323244">
         <span class="h1">
          RATIONALE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for intralesional therapy is simple: to deliver a medication directly into a specific skin lesion to treat local tissues with minimal systemic effects. The skin also serves as a reservoir, allowing medication deposited in the dermis to be delivered over a certain period of time, resulting in prolonged therapy while avoiding or minimizing the adverse effects of systemic therapy.
        </p>
        <p class="headingAnchor" id="H205304705">
         <span class="h1">
          CORTICOSTEROID FORMULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          Triamcinolone
         </a>
         acetonide is the corticosteroid most widely used for intralesional injection, although
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         acetate are used by some clinicians. Triamcinolone preparations are available as micronized suspensions. Characteristics associated with micronized suspensions that make them desirable for intralesional administration are the small size of the corticosteroid particles, stability at room temperature, and ease of resuspension with gentle mixing [
         <a href="#rid9">
          9
         </a>
         ]. Small corticosteroid crystals are more efficiently delivered to the treatment site, thereby decreasing the total administered dose of the drug and reducing the risk of systemic side effects and skin atrophy. In addition, because micronized corticosteroid crystals are in a depot form, the active ingredients are stored in the tissues and released over a period of weeks, making this type of corticosteroid delivery system well suited for the treatment of chronic, inflammatory dermatoses [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for intralesional corticosteroid therapy include acute and chronic, inflammatory processes [
         <a href="#rid10">
          10
         </a>
         ]; hyperplastic and hypertrophic skin disorders; and conditions that typically have a favorable response to systemic and topical corticosteroids  (
         <a class="graphic graphic_table graphicRef143371" href="/z/d/graphic/143371.html" rel="external">
          table 1
         </a>
         ). Examples of chronic, inflammatory dermatoses that are particularly amenable to this type of extended action include thick psoriasis plaques, hypertrophic discoid lupus erythematosus, lichen simplex chronicus, and prurigo nodularis. Other conditions effectively treated with intralesional corticosteroids include alopecia areata, cutaneous sarcoidosis, granuloma annulare, and hypertrophic scars and keloids.
        </p>
        <p class="headingAnchor" id="H3097345676">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intralesional corticosteroid injections may not be indicated in the following situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the possibility of infection is present, either as the etiology of the lesion or as a secondary sequela.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes is not an absolute contraindication to intralesional corticosteroid therapy. Both topical and intralesional corticosteroids can increase blood glucose levels, typically related to the potency and quantity of the agent used [
         <a href="#rid11">
          11,12
         </a>
         ]. Caution should be used and appropriate monitoring performed when treating a person with diabetes with corticosteroids of any type.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3726705933">
         <span class="h1">
          REDUCING INJECTION PAIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         While pain is rarely associated with low concentrations of corticosteroids, patients may experience pain during, and for a short time after, injection of higher concentrations (eg, 20 to 40 mg/mL). Injection of keloids or sensitive body sites (eg, perioral area, palm of the hand) is also associated with considerable pain.
        </p>
        <p>
         Methods employed to reduce injection pain in settings where pain is problematic (eg, treatment of keloids, treating children) include [
         <a href="#rid13">
          13-19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination of corticosteroid with local anesthetic
         </strong>
         – Some clinicians use 1%
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         as diluent for corticosteroids to reduce pain. However, a study comparing
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and unbuffered lidocaine as diluents found no significant difference in discomfort between the two [
         <a href="#rid20">
          20
         </a>
         ]. Another study found that pain scores were actually higher for injections containing
         <a class="drug drug_general" data-topicid="9559" href="/z/d/drug information/9559.html" rel="external">
          lidocaine-epinephrine
         </a>
         versus saline [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior local anesthesia
         </strong>
         – Local anesthesia can be administered prior to the injection on the periphery of the treatment site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical anesthetics
         </strong>
         – Topical anesthetics, such as eutectic mixture of local anesthetics (EMLA) cream or lidocaine-impregnated tape, can be applied to the injection site prior to the injection. Though they significantly reduce pain, the drawback to topical EMLA cream and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         patches is that they require application of 60 to 120 minutes prior to injections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cooling
         </strong>
         – Cooling the area with light liquid nitrogen application, cold packs, or cold air device.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vibration anesthesia
         </strong>
         – A vibrating device is applied to the skin adjacent to the injection site for the duration of the injection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          EQUIPMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most intralesional therapy is administered via needle, although a few clinicians prefer jet injection devices. The needles are placed on 1 or 3 mL Luer lock syringes to prevent the needle separating from the syringe under the pressure of injection. One milliliter syringes are most frequently used because the quantity of medication delivered is usually in the tenths or even hundredths of a milliliter, and the smaller syringe allows for greater quantitative accuracy.
        </p>
        <p>
         Typically, 30- or 27-gauge needles are generally used, although 25-gauge needles may be preferable when injecting lesions with dense or thickened tissue, such as scars and keloids. Thirty-gauge needles are the most desirable and widely used by dermatologists because they produce less discomfort when penetrating the skin and prevent rapid injection, which is associated with increased pain. Smaller-gauge needles also allow greater precision in injecting the desired quantity of the drug. A larger bore needle (21 or 22 gauge) is used to draw up the solution and to dilute the corticosteroid with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , then it is removed and replaced with the small injecting needle.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          Saline
         </a>
         is an excellent diluent for all corticosteroids, but some clinicians prefer to dilute with the local anesthetic
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         . (See
         <a class="local">
          'Reducing injection pain'
         </a>
         above.)
        </p>
        <p>
         Other standard equipment for injection includes nonsterile gloves, an alcohol swab, 4x4 gauze, adhesive bandage, and protective eyewear.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          MIXING THE SOLUTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          Triamcinolone
         </a>
         acetonide is available in 10, 40, and 80 mg/mL multidose vials. When using corticosteroids from multidose vials, it is advised that dilution of the corticosteroid be done in the syringe immediately prior to injection. The final concentration should just be sufficient to treat the lesion and low enough to avoid local or systemic side effects.
        </p>
        <p>
         To dilute a single dose of a corticosteroid, it is necessary to gently shake the corticosteroid bottle to resuspend the particles. Sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         for injection or 0.5% or 1%
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         without
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         may be used as the diluent, especially when using high corticosteroid concentrations or injecting more than 1 mL into a single site  (
         <a class="graphic graphic_table graphicRef129499" href="/z/d/graphic/129499.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To obtain a 2 mg/mL concentration, draw up 0.4 mL of
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         for each 0.1 mL of 10 mg/mL of
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To obtain a 20 mg/mL dilution, draw up 0.5 mL of 1%
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         for each 0.5 mL of 40 mg/mL
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Immediately
         </strong>
         before injecting a lesion, gently shake or roll the syringe to ensure even suspension of the drug in the diluent and, consequently, even delivery into the tissue. It has been shown that waiting longer than five minutes between mixing and injecting can result in the formation of large and potentially harmful aggregates [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Pitfalls'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3496661807">
         <span class="h1">
          DOSING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of corticosteroid doses for select conditions amenable to treatment with intralesional corticosteroids are illustrated in the table  (
         <a class="graphic graphic_table graphicRef66500" href="/z/d/graphic/66500.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         In general, acute, inflammatory lesions (eg, acne cysts) and lesions in thin-skinned areas (eg, the face and central chest) require lower corticosteroid concentrations and smaller drug quantities than more chronic lesions (eg, psoriasis, lichen simplex chronicus, keloids) and lesions in thick-skinned areas (eg, the scalp and back) [
         <a href="#rid10">
          10
         </a>
         ]. However, there is considerable variation among experts regarding matching the concentration and volume of the corticosteroid injected to the type of lesion being treated.
        </p>
        <p>
         Patients should be advised that the first treatment may not be completely effective, and more than one injection may be necessary.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          INJECTION TECHNIQUE
         </span>
        </p>
        <p class="headingAnchor" id="H3286681118">
         <span class="h2">
          General principles
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because most pathologic changes in inflammatory skin lesions occur in the dermis, it is in this layer of skin that corticosteroids should be deposited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caution should be exerted when treating facial and periocular areas to avoid accidental intravascular injection (see
         <a class="local">
          'Pitfalls'
         </a>
         below). Details on anatomic sites at increased risk of vascular complications are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/103371.html" rel="external">
          "Anatomic danger zones for facial injection of soft tissue fillers"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinician should first prepare the skin with alcohol, then insert the needle at a 45 to 90 degree angle into the lesion to the level of mid-dermis, then slowly inject the drug  (
         <a class="graphic graphic_picture graphicRef143104" href="/z/d/graphic/143104.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef75695" href="/z/d/graphic/75695.html" rel="external">
          picture 2
         </a>
         ). When deposited correctly into the mid-dermis, the skin rises slightly and blanches  (
         <a class="graphic graphic_picture graphicRef69986" href="/z/d/graphic/69986.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enough material is injected to just slightly raise the skin surface. Often, this is only tenths of a milliliter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For large lesions, the needle should be withdrawn partially and redirected to cover additional areas, or the needle can be removed and reinserted in another site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Caution is needed to avoid injecting into subcutaneous tissue; this is easy to recognize because the injected solution flows easily into subcutaneous fat, while resistance is felt when correctly injecting into dermis. Correct injection technique depends on awareness of the different thicknesses of the epidermis and dermis in different body sites, at various ages, and in specific diseases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having completed the injection, gauze is held lightly over the site to stop any bleeding. Occasionally, an adhesive bandage is placed if bleeding continues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hand hygiene is required before and after all patient encounters, even if gloves are worn. Care must be exercised to prevent accidental self-injury, such as not attempting to recap the needle, use of self-sheathing needles, and proper disposal in an approved puncture-resistant container (see
         <a class="medical medical_review" href="/z/d/html/3647.html" rel="external">
          "Prevention of hepatitis B virus and hepatitis C virus infection among health care providers", section on 'Minimizing risk'
         </a>
         ). Because high injection pressures are sometimes required to inject into keloids and other thick dermal plaques, appropriate protective eyewear is essential to avoid splash injury.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1918356905">
         <span class="h2">
          Special situations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cysts
         </strong>
         – When injecting inflamed acne cysts or cysts and sinuses of hidradenitis suppurativa, the tissue immediately surrounding the cyst or sinus, but still well within the zone of inflammation, is the target area. Protective eyewear is strongly advised, especially when dealing with cystic lesions, to prevent material discharged from the injection or the cyst from splashing into the eyes. (See
         <a class="medical medical_review" href="/z/d/html/7605.html" rel="external">
          "Hidradenitis suppurativa: Management", section on 'Intralesional corticosteroids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Keloids and hypertrophic scars
         </strong>
         – Keloids and hypertrophic scars are directly injected with corticosteroids. However, thick and long-standing keloids are often so tough that they must be softened by pretreatment for 5 to 20 seconds with liquid nitrogen. Alternatively, an injection can be performed immediately peripheral to the affected tissue, directing the needle toward the keloid  (
         <a class="graphic graphic_picture graphicRef73191" href="/z/d/graphic/73191.html" rel="external">
          picture 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">
          "Keloids and hypertrophic scars", section on 'Corticosteroid injection, tape/plaster, and ointment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Keloids often need multiple treatments three to four weeks apart until there is adequate flattening of the lesion. It is not unusual to use
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         in strengths of up to 40 mg/mL. However, most dermatologists recommend beginning treatment with triamcinolone 5 to 10 mg/mL to avoid excessive, and sometimes permanent, atrophy and hypopigmentation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          ADVERSE EFFECTS AND PITFALLS
         </span>
        </p>
        <p class="headingAnchor" id="H1712927054">
         <span class="h2">
          Local adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse effects of intralesional corticosteroid injections are local. These include atrophy  (
         <a class="graphic graphic_picture graphicRef121649" href="/z/d/graphic/121649.html" rel="external">
          picture 5
         </a>
         ), hypopigmentation, and rarely, sterile abscess formation. Atrophy and pigment changes usually resolve over several weeks but occasionally persist longer and are sometimes permanent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrophy
         </strong>
         – Atrophy can occur in the following situations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The drug is deposited too deeply into the skin (eg, fat).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The dose of the corticosteroid is higher than needed to treat the condition; the risk is higher when using a
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         acetonide concentration higher than 5 mg/mL. However, even with appropriate dosing, atrophy may occur because the particles release the corticosteroid over weeks, and atrophy may not appear immediately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Steroid particles have not been well suspended prior to injection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeated treatments are administered in the same site.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most cases of atrophy, no treatment is needed, as there is resolution with time. However, some atrophic lesions may be persistent. Dermal fillers, such as
         <a class="drug drug_general" data-topicid="10301" href="/z/d/drug information/10301.html" rel="external">
          poly-L-lactic acid
         </a>
         ,
         <a class="drug drug_general" data-topicid="8643" href="/z/d/drug information/8643.html" rel="external">
          hyaluronic acid
         </a>
         , and calcium hydroxylapatite, are used for a variety of cutaneous atrophies due to other causes, but there are no published data specific to steroid-induced atrophy. (See
         <a class="medical medical_review" href="/z/d/html/16532.html" rel="external">
          "Injectable soft tissue fillers: Overview of clinical use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypopigmentation
         </strong>
         – Hypopigmentation and depigmentation can occur with corticosteroid injections. It is most noticeable in individuals with darkly pigmented skin (skin phototypes IV to VI) and is thought to be due to a direct cytotoxic effect of the corticosteroids on melanocytes. Greater amounts and concentrations of corticosteroids (such as those used in the treatment of keloids) increase the risk for loss of pigment. Pigment changes may last up to a year. Patients, especially those with darkly pigmented skin, should be cautioned about this potential complication [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sterile abscess
         </strong>
         – Although uncommon, sterile abscesses can occur after corticosteroid injections. A sterile abscess is one due to inflammation around foreign material in the skin rather than an infectious agent. The steroid microparticles may be the cause of this reaction. A sterile abscess can appear as an asymptomatic or slightly painful, pink or skin-colored nodule, papule, or pustule at the injection site, or it may be a firm nodule in the skin. If pustular, the abscess can be drained by stabbing the pustule with a number 11 blade and draining the contents.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1642857292">
         <span class="h2">
          Systemic adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic adverse effects of intralesional corticosteroids due to systemic absorption are infrequent, especially when corticosteroids are used in low doses and at three- to four-week intervals as generally recommended for the treatment of cutaneous lesions. However, there are reports of hyperglycemia, Cushing syndrome, and adrenal suppression following intralesional administration of corticosteroids [
         <a href="#rid11">
          11,24-26
         </a>
         ]. Repeated, frequent injections producing a high cumulative dose of a corticosteroid (more than 40 mg per month) may result in systemic adverse effects, especially in children.
        </p>
        <p class="headingAnchor" id="H1003167609">
         <span class="h2">
          Pitfalls
         </span>
         <span class="headingEndMark">
          —
         </span>
         Frequent pitfalls related to intralesional injections include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Using too much of or too concentrated corticosteroid
         </strong>
         – It is preferable to inject corticosteroids in small amounts and low concentrations and repeat the injection in three to four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placing the corticosteroid incorrectly into the skin
         </strong>
         – When deposited in the subcutaneous layer, the atrophic effect may be exaggerated and the therapeutic anti-inflammatory effect minimized. Likewise, injecting too high in the skin, in the upper dermis and epidermis, may cause sloughing of the skin. Additionally, placement close to the epidermis may increase the risk for loss of pigment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Accidental intravascular injection
         </strong>
         –
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          Triamcinolone
         </a>
         is composed of microcrystal particles that may form aggregates. Serious adverse effects may occur from inadvertent intravascular injection, especially when triamcinolone is administered in combination with
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , which results in formation of large particle aggregates (up to 500 micron) and risk of arterial embolism [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, in-depth knowledge of the facial anatomy and vasculature is required when injecting the face or periorbital areas to avoid accidental intravascular injection that may result in retinal artery occlusion and blindness [
         <a href="#rid28">
          28-31
         </a>
         ]. In a 2021 systematic review of 49 patients with steroid-induced vision loss, occlusion occurred in the ophthalmic or central retinal occlusion in most cases,
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         was most frequently used, and injection was performed in the nasal and periocular areas in most cases [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H350591348">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83435.html" rel="external">
          "Patient education: Keloids (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Intralesional injection is a technique used to administer medication directly into the skin. The anti-inflammatory and atrophogenic effects of injected corticosteroids are useful for the treatment of a variety of skin disorders. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Equipment
         </strong>
         – A one milliliter Luer lock syringe with 30- or 27-gauge needles, rather than a larger syringe, is typically used, as it allows for better control of the quantity injected. A 25-gauge needle is preferred when injecting lesions with dense or thickened tissue, such as scars. (See
         <a class="local">
          'Equipment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixing the solution
         </strong>
         –
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          Triamcinolone
         </a>
         acetonide is the corticosteroid most frequently used for intralesional injections and is available as a micronized suspension. Dilution with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         may be required to achieve the desired dose  (
         <a class="graphic graphic_table graphicRef129499" href="/z/d/graphic/129499.html" rel="external">
          table 2
         </a>
         ). The syringe should be shaken or rolled immediately prior to injection to ensure even suspension of the drug during delivery. (See
         <a class="local">
          'Mixing the solution'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Injection technique
         </strong>
         – The dermis is typically targeted during intralesional corticosteroid injections. The needle should be inserted at a 45 to 90 degree angle into the lesion  (
         <a class="graphic graphic_picture graphicRef143104" href="/z/d/graphic/143104.html" rel="external">
          picture 1
         </a>
         ). The injection technique and the corticosteroid concentration may vary according to lesion type and site. (See
         <a class="local">
          'Injection technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Potential side effects of intralesional corticosteroid injection include cutaneous atrophy  (
         <a class="graphic graphic_picture graphicRef121649" href="/z/d/graphic/121649.html" rel="external">
          picture 5
         </a>
         ), hypopigmentation, and abscess formation. The lowest dose required to achieve the desired effect should be utilized to minimize this risk. Systemic side effects may occur in patients receiving frequent high doses of corticosteroids. (See
         <a class="local">
          'Adverse effects and pitfalls'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           HOLLANDER A. Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiotic Med Clin Ther (New York) 1961; 8:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang S, Kampp J. Common Dermatologic Procedures. Med Clin North Am 2015; 99:1305.
          </a>
         </li>
         <li class="breakAll">
          Madden S, Ho VC. Dermatologic therapy. In: Dermatology, 3rd ed, Moschella S, Hurley HH (Eds), WB Saunders, 1992. p.2200.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince GT, Cameron MC, Fathi R, Alkousakis T. Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. J Drugs Dermatol 2018; 17:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg 2008; 34:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly E, Duval-Modeste A, Sabatier R, et al. Intralesional rituximab treatment for atypical refractory granuloma faciale. Ann Dermatol Venereol 2021; 148:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Väkevä L, Ranki A, Mälkönen T. Intralesional Rituximab Treatment for Primary Cutaneous B-cell Lymphoma: Nine Finnish Cases. Acta Derm Venereol 2016; 96:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñate Y, Hernández-Machín B, Pérez-Méndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callen JP. Intralesional corticosteroids. J Am Acad Dermatol 1981; 4:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards RN. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg 2010; 14:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming P, Drazek L, Shaw JC. Hyperglycemia following intralesional corticosteroid injection in a patient with type I diabetes mellitus. J Cutan Med Surg 2014; 18:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib G, Safia A. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol 2009; 28:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugo-Janer G, Padial M, Sánchez JL. Less painful alternatives for local anesthesia. J Dermatol Surg Oncol 1993; 19:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park KY, Lee Y, Hong JY, et al. Vibration Anesthesia for Pain Reduction During Intralesional Steroid Injection for Keloid Treatment. Dermatol Surg 2017; 43:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra S. Safe and less painful injection of triamcenolone acetonide into a keloid--a technique. J Plast Reconstr Aesthet Surg 2010; 63:e205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tosa M, Murakami M, Hyakusoku H. Effect of lidocaine tape on pain during intralesional injection of triamcinolone acetonide for the treatment of keloid. J Nippon Med Sch 2009; 76:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Qarqaz F, Al-Aboosi M, Al-shiyab D, Al Dabbagh Z. Using cold air for reducing needle-injection pain. Int J Dermatol 2012; 51:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tierney EP, Hanke CW. The effect of cold-air anesthesia during fractionated carbon-dioxide laser treatment: Prospective study and review of the literature. J Am Acad Dermatol 2012; 67:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fix WC, Chiesa-Fuxench ZC, Shin T, et al. Use of a vibrating kinetic anesthesia device reduces the pain of lidocaine injections: A randomized split-body trial. J Am Acad Dermatol 2019; 80:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usanakornkul A, Burusapat C. A Topical Anesthetic and Lidocaine Mixture for Pain Relief During Keloid Treatment: A Double-Blind, Randomized Controlled Trial. Dermatol Surg 2017; 43:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakria D, Patrinely JR Jr, Dewan AK, et al. Intralesional corticosteroid injections are less painful without local anesthetic: a double-blind, randomized controlled trial. J Dermatolog Treat 2022; 33:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orduna-Valls JM, Cedeno DL, Nebreda-Clavo C, et al. Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation. Pain Physician 2020; 23:E417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ud-Din S, Bayat A. Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature. Br J Dermatol 2013; 169 Suppl 3:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sukhumthammarat W, Putthapiban P, Sriphrapradang C. Local Injection of Triamcinolone Acetonide: A Forgotten Aetiology of Cushing's Syndrome. J Clin Diagn Res 2017; 11:OR01.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morkane C, Gregory JW, Watts P, Warner JT. Adrenal suppression following intralesional corticosteroids for periocular haemangiomas. Arch Dis Child 2011; 96:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fredman R, Tenenhaus M. Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey. Burns 2013; 39:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahezi SE, Mohamed SE, Lederman A, Beck AP. Aggregation properties of triamcinolone acetonide injection in human serum: considerations when performing epidural steroid injections. J Pain Res 2019; 12:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chavala SH, Williamson JF, Postel EA. Embolic central retinal artery occlusion after subcutaneous auricular steroid injection. Lancet 2016; 387:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raufi NN, Wisely CE, Leyngold IM, Vajzovic L. Ophthalmic and Central Retinal Artery Occlusion Following Triamcinolone Injection of the Lacrimal Gland. JAMA Ophthalmol 2019; 137:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayikcioglu OR, Altinisik M, Inan S, Kurt E. Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide. J Curr Ophthalmol 2019; 31:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu OG, Chunming L, Juanjuan W, Xiaoyan X. Central retinal artery occlusion and cerebral inrfaction following forehead injection with a corticosteroid suspension for vitiligo. Indian J Dermatol Venereol Leprol 2014; 80:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SSE, Barmettler A. Vision Loss Secondary to Facial and Periorbital Steroid Injection: A Systematic Review. Ophthalmic Plast Reconstr Surg 2021; 37:511.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5568 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13715299" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Intralesional injections of triamcinolone acetonide; a therapy for dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26476254" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Common Dermatologic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26476254" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Common Dermatologic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29537445" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18616538" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Bleomycin in dermatology: a review of intralesional applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34456047" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intralesional rituximab treatment for atypical refractory granuloma faciale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26525093" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intralesional Rituximab Treatment for Primary Cutaneous B-cell Lymphoma: Nine Finnish Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22356294" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7217384" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Intralesional corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20128986" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Update on intralesional steroid: focus on dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25008445" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hyperglycemia following intralesional corticosteroid injection in a patient with type I diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18853221" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383150" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Less painful alternatives for local anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28244902" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Vibration Anesthesia for Pain Reduction During Intralesional Steroid Injection for Keloid Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19395330" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Safe and less painful injection of triamcenolone acetonide into a keloid--a technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19305104" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effect of lidocaine tape on pain during intralesional injection of triamcinolone acetonide for the treatment of keloid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22715833" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Using cold air for reducing needle-injection pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22695102" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The effect of cold-air anesthesia during fractionated carbon-dioxide laser treatment: Prospective study and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30130597" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Use of a vibrating kinetic anesthesia device reduces the pain of lidocaine injections: A randomized split-body trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28027198" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A Topical Anesthetic and Lidocaine Mixture for Pain Relief During Keloid Treatment: A Double-Blind, Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33760691" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intralesional corticosteroid injections are less painful without local anesthetic: a double-blind, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32709188" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24098903" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28764237" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Local Injection of Triamcinolone Acetonide: A Forgotten Aetiology of Cushing's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21321258" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adrenal suppression following intralesional corticosteroids for periocular haemangiomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23092701" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30936741" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Aggregation properties of triamcinolone acetonide injection in human serum: considerations when performing epidural steroid injections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26631356" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Embolic central retinal artery occlusion after subcutaneous auricular steroid injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31600385" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ophthalmic and Central Retinal Artery Occlusion Following Triamcinolone Injection of the Lacrimal Gland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30899855" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24685869" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Central retinal artery occlusion and cerebral inrfaction following forehead injection with a corticosteroid suspension for vitiligo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33481540" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Vision Loss Secondary to Facial and Periorbital Steroid Injection: A Systematic Review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
